The biological characteristics of chromogranin A and its role as a circulating marker in neuroendocrine tumours

Leonardo Ferrari, Ettore Seregni, Emilio Bajetta, Antonia Martinetti, Emilio Bombardieri

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

This paper reviews the biology of chromogranin A (CgA) and CgA-derived peptides and their possible role as markers for neuroendocrine tumours (NETs). NETs are neoplasms characterized by a low proliferation rate and, in some cases, a favourable prognosis. NETs often overproduce and release biologically active substances that are responsible for severe syndromes. The hormones and the biogenic amines released by biologically active NETs are currently used as biomarkers, but there is a need for sensitive markers for those NETs that are 'biochemically silent'. Circulating CgA levels have been demonstrated to be augmented in NET patients irrespective of the presence of syndromes related to hormone overproduction. Because of the high sensitivity and specificity of CgA, this glycoprotein can be successfully used in diagnosis, prognosis and follow-up of NETs. CgA blood evaluation seems of particular interest in the managements of the gastroenteropancreatic tract NETs and in carcinoids.

Original languageEnglish
Pages (from-to)3415-3427
Number of pages13
JournalAnticancer Research
Volume19
Issue number4 C
Publication statusPublished - 1999

Fingerprint

Chromogranin A
Neuroendocrine Tumors
Hormones
Biogenic Amines
Carcinoid Tumor
Glycoproteins
Biomarkers
Sensitivity and Specificity
Peptides

Keywords

  • Autonomous nervous system
  • Carcinoid
  • Chromogranin A
  • Essential hypertension
  • Islet-cell pancreas tumours
  • Medullary thyroid carcinoma
  • Neuroblastoma
  • Neuroendocrine tumours
  • Pancreastatin
  • Phaeochromocytoma
  • Small cell lung cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

The biological characteristics of chromogranin A and its role as a circulating marker in neuroendocrine tumours. / Ferrari, Leonardo; Seregni, Ettore; Bajetta, Emilio; Martinetti, Antonia; Bombardieri, Emilio.

In: Anticancer Research, Vol. 19, No. 4 C, 1999, p. 3415-3427.

Research output: Contribution to journalArticle

@article{fe5f1c670aea43fcb152f354b60d74d1,
title = "The biological characteristics of chromogranin A and its role as a circulating marker in neuroendocrine tumours",
abstract = "This paper reviews the biology of chromogranin A (CgA) and CgA-derived peptides and their possible role as markers for neuroendocrine tumours (NETs). NETs are neoplasms characterized by a low proliferation rate and, in some cases, a favourable prognosis. NETs often overproduce and release biologically active substances that are responsible for severe syndromes. The hormones and the biogenic amines released by biologically active NETs are currently used as biomarkers, but there is a need for sensitive markers for those NETs that are 'biochemically silent'. Circulating CgA levels have been demonstrated to be augmented in NET patients irrespective of the presence of syndromes related to hormone overproduction. Because of the high sensitivity and specificity of CgA, this glycoprotein can be successfully used in diagnosis, prognosis and follow-up of NETs. CgA blood evaluation seems of particular interest in the managements of the gastroenteropancreatic tract NETs and in carcinoids.",
keywords = "Autonomous nervous system, Carcinoid, Chromogranin A, Essential hypertension, Islet-cell pancreas tumours, Medullary thyroid carcinoma, Neuroblastoma, Neuroendocrine tumours, Pancreastatin, Phaeochromocytoma, Small cell lung cancer",
author = "Leonardo Ferrari and Ettore Seregni and Emilio Bajetta and Antonia Martinetti and Emilio Bombardieri",
year = "1999",
language = "English",
volume = "19",
pages = "3415--3427",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "4 C",

}

TY - JOUR

T1 - The biological characteristics of chromogranin A and its role as a circulating marker in neuroendocrine tumours

AU - Ferrari, Leonardo

AU - Seregni, Ettore

AU - Bajetta, Emilio

AU - Martinetti, Antonia

AU - Bombardieri, Emilio

PY - 1999

Y1 - 1999

N2 - This paper reviews the biology of chromogranin A (CgA) and CgA-derived peptides and their possible role as markers for neuroendocrine tumours (NETs). NETs are neoplasms characterized by a low proliferation rate and, in some cases, a favourable prognosis. NETs often overproduce and release biologically active substances that are responsible for severe syndromes. The hormones and the biogenic amines released by biologically active NETs are currently used as biomarkers, but there is a need for sensitive markers for those NETs that are 'biochemically silent'. Circulating CgA levels have been demonstrated to be augmented in NET patients irrespective of the presence of syndromes related to hormone overproduction. Because of the high sensitivity and specificity of CgA, this glycoprotein can be successfully used in diagnosis, prognosis and follow-up of NETs. CgA blood evaluation seems of particular interest in the managements of the gastroenteropancreatic tract NETs and in carcinoids.

AB - This paper reviews the biology of chromogranin A (CgA) and CgA-derived peptides and their possible role as markers for neuroendocrine tumours (NETs). NETs are neoplasms characterized by a low proliferation rate and, in some cases, a favourable prognosis. NETs often overproduce and release biologically active substances that are responsible for severe syndromes. The hormones and the biogenic amines released by biologically active NETs are currently used as biomarkers, but there is a need for sensitive markers for those NETs that are 'biochemically silent'. Circulating CgA levels have been demonstrated to be augmented in NET patients irrespective of the presence of syndromes related to hormone overproduction. Because of the high sensitivity and specificity of CgA, this glycoprotein can be successfully used in diagnosis, prognosis and follow-up of NETs. CgA blood evaluation seems of particular interest in the managements of the gastroenteropancreatic tract NETs and in carcinoids.

KW - Autonomous nervous system

KW - Carcinoid

KW - Chromogranin A

KW - Essential hypertension

KW - Islet-cell pancreas tumours

KW - Medullary thyroid carcinoma

KW - Neuroblastoma

KW - Neuroendocrine tumours

KW - Pancreastatin

KW - Phaeochromocytoma

KW - Small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=0033452512&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033452512&partnerID=8YFLogxK

M3 - Article

C2 - 10629629

AN - SCOPUS:0033452512

VL - 19

SP - 3415

EP - 3427

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 4 C

ER -